Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? The Colombian case

Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? The Colombian case

Abstract Background High pharmaceutical expenditure is one of the main concerns for policymakers worldwide. In Colombia, a middle-income country, outpatient prescription represents over 10% of total health expenditure in the mandatory benefits package (POS), and close to 90% in the complementary gov...

Full description

Bibliographic Details
Main Authors: Sergio I. Prada, Victoria E. Soto, Tatiana S. Andia, Claudia P. Vaca, Álvaro A. Morales, Sergio R. Márquez, Alejandro Gaviria
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Pharmaceutical price control
Public expenditure
Developing countries
Middle income
Online Access:http://link.springer.com/article/10.1186/s12962-018-0092-0

Internet

http://link.springer.com/article/10.1186/s12962-018-0092-0

Similar Items